Deutsche Bank AG Purchases New Stake in C4 Therapeutics, Inc. $CCCC

Deutsche Bank AG purchased a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,225 shares of the company’s stock, valued at approximately $74,000. Deutsche Bank AG owned 0.07% of C4 Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. increased its position in C4 Therapeutics by 5.7% in the 4th quarter. Soleus Capital Management L.P. now owns 6,978,942 shares of the company’s stock worth $25,124,000 after purchasing an additional 374,946 shares during the last quarter. Tang Capital Management LLC grew its stake in shares of C4 Therapeutics by 28.6% in the 4th quarter. Tang Capital Management LLC now owns 900,000 shares of the company’s stock valued at $3,240,000 after buying an additional 200,000 shares in the last quarter. Northern Trust Corp increased its holdings in C4 Therapeutics by 1.1% in the fourth quarter. Northern Trust Corp now owns 495,043 shares of the company’s stock worth $1,782,000 after buying an additional 5,223 shares during the last quarter. SG Americas Securities LLC bought a new position in C4 Therapeutics during the first quarter valued at approximately $680,000. Finally, Millennium Management LLC raised its position in C4 Therapeutics by 1,548.3% during the fourth quarter. Millennium Management LLC now owns 360,125 shares of the company’s stock valued at $1,296,000 after acquiring an additional 338,277 shares in the last quarter. Institutional investors and hedge funds own 78.81% of the company’s stock.

C4 Therapeutics Stock Up 2.0%

Shares of CCCC stock opened at $2.60 on Tuesday. C4 Therapeutics, Inc. has a 12 month low of $1.09 and a 12 month high of $7.22. The firm has a market cap of $185.04 million, a PE ratio of -1.65 and a beta of 2.98. The stock has a 50 day moving average of $2.16 and a 200-day moving average of $1.89.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%. The firm had revenue of $6.46 million for the quarter, compared to the consensus estimate of $5.24 million. As a group, equities analysts predict that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Zacks Research lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Wall Street Zen lowered C4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, C4 Therapeutics currently has an average rating of “Hold” and an average price target of $8.00.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.